Simulations Plus (NASDAQ:SLP) Reaches New 1-Year Low Following Insider Selling

Simulations Plus, Inc. (NASDAQ:SLP) shares hit a new 52-week low during trading on Thursday following insider selling activity. The stock traded as low as $30.15 and last traded at $30.22, with a volume of 12580 shares trading hands. The stock had previously closed at $30.85.

Specifically, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total transaction of $625,200.00. Following the transaction, the director now owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Analysts Set New Price Targets

SLP has been the topic of several recent analyst reports. Craig Hallum reiterated a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a report on Wednesday, July 3rd. KeyCorp assumed coverage on shares of Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target on the stock. Oppenheimer upped their price objective on Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 13th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday, September 12th. Finally, JMP Securities started coverage on Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Simulations Plus Stock Performance

The business’s fifty day simple moving average is $34.83 and its 200 day simple moving average is $41.76. The stock has a market cap of $604.64 million, a price-to-earnings ratio of 62.96 and a beta of 0.69.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Tuesday, July 2nd. The technology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.04. The company had revenue of $18.54 million for the quarter, compared to the consensus estimate of $17.92 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. Simulations Plus’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.20 EPS. As a group, analysts forecast that Simulations Plus, Inc. will post 0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Simulations Plus

Institutional investors have recently modified their holdings of the stock. First National Bank of Omaha bought a new stake in shares of Simulations Plus in the 4th quarter valued at approximately $337,000. Ranger Investment Management L.P. raised its holdings in shares of Simulations Plus by 1.4% during the fourth quarter. Ranger Investment Management L.P. now owns 931,132 shares of the technology company’s stock worth $41,668,000 after purchasing an additional 12,505 shares during the period. Wasatch Advisors LP raised its holdings in shares of Simulations Plus by 45.6% during the fourth quarter. Wasatch Advisors LP now owns 279,558 shares of the technology company’s stock worth $12,510,000 after purchasing an additional 87,516 shares during the period. Ophir Asset Management Pty Ltd bought a new position in shares of Simulations Plus in the 4th quarter worth about $7,156,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Simulations Plus by 36.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,426 shares of the technology company’s stock valued at $511,000 after buying an additional 3,072 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.